Analysis Medivir AB (MVRBF)
6/5/2024
Analysis of Medivir AB (MVRBF)
Medivir AB (MVRBF) has been trading at a consistent price of 0.82 for the past several days. The Relative Strength Index (RSI) indicator is at 0.00, indicating a neutral position. The Moving Average Convergence Divergence (MACD) indicator is not available, suggesting a lack of trend direction.In terms of moving averages, the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all at 0.82, reflecting the stable price of the stock.
Overall, based on the available data, it seems that Medivir AB is currently experiencing a period of price stability with no clear trend direction indicated by the technical indicators. Further analysis and monitoring may be needed to identify potential shifts in the stock's price movement.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a wide range of opinions on the future price of the security, with the low end being $164, the high end being $275, and the average forecast at $204.58. The current price of the security is $192.25, which is below the median and average forecasted prices. Investors should consider these forecasts along with other factors when making investment decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released After Hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows good returns on assets and equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock has a beta of 1.264 and has been trading within a range between its fifty-two-week low and high.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with a high price-to-book ratio and price-to-sales ratio. The enterprise value to EBITDA and revenue ratios are also notable.
The stock price summary includes moving averages, fifty-two-week low and high prices, and the percentage change over the past year.
Lastly, dividends and splits information shows the company's dividend dates, payout ratios, and dividend yields. The company has a history of dividends and stock splits, with both forward and trailing annual dividend rates and yields provided.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. Earnings before interest and taxes (EBIT) have shown an increasing trend, reaching $117.7 billion in 2023.
5. Net income has also been increasing, reaching $97 billion in 2023.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to maintain a healthy operating income and pretax income over the years.
8. The company's non-operating interest income has been fluctuating, which could impact its overall financial performance.
9. The number of basic and diluted shares outstanding has remained relatively stable over the years.
10. Overall, the company's revenue and profitability have shown positive growth trends, indicating a strong financial performance.
Balance Sheet
These are balance sheets. Here are the conclusions based on the provided data:1. The total assets have been increasing over the years, reaching the highest value in 2023 at $352,583,000,000.
2. Current assets fluctuate from year to year, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2023 at $209,017,000,000.
4. Total liabilities have also been increasing, reaching the highest value in 2023 at $290,437,000,000.
5. Shareholders' equity has been fluctuating, with the highest value in 2019 at $90,488,000,000.
6. The company has been relying more on non-current assets to finance its operations, as seen in the increasing trend of non-current assets compared to current assets.
7. The company has been taking on more debt over the years, as indicated by the increasing total liabilities.
8. The fluctuations in shareholders' equity suggest varying profitability or capital injections over the years.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing over the years, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.6% in the current year and 9.7% in the next year.
- For the current quarter and the next quarter, the growth rate is estimated to be around 5.1%.
- Over the next 5 years, the company is projected to have a compound annual growth rate (CAGR) of approximately 9.7%.
- However, in the past 5 years, the company had a higher growth rate with a CAGR of about 20.1%.
Overall, it seems that the company is expected to maintain a steady growth rate in the upcoming periods compared to the higher growth rate seen in the past 5 years.
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
